Systemic inflammation and cardiac surgery: insights from the RECCAS trial

Abstract

The authors concluded that haemoadsorption (HA) did not result in significant reductions in cytokine levels on intensive care unit (ICU) admission or subsequently and observed no significant differences in organ dysfunction, ICU and hospital lengths of stay, or mortality rates. Age is a key determinant of inflammatory response severity, with evidence suggesting that older adults exhibit reduced endothelial activation, impaired cytokine signaling, and attenuated innate immune responses, as highlighted in sepsis-related studies [2]. [...]nearly half of the patients did not undergo bypass surgery, valve surgery, or a combination of both, which differs significantly from the populations typically reported in cardiac surgery trials [3, 4]. [...]the RECCAS trial represents an important contribution to the growing body of literature on systemic inflammation management in cardiac surgery.